Ipilimumab vs Rituximab

## Ipilimumab vs Rituximab: Overview

This comparison examines the pharmacological differences between **Ipilimumab** and **Rituximab**.

## Mechanism of Action

**Ipilimumab**: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

**Rituximab**: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

## Pharmacokinetics

**Half-life**: Ipilimumab — 14.7 days; Rituximab — 22 days.

## Chemical Properties

**Type**: Ipilimumab — Antibody; Rituximab — Antibody.